公开(公告)号：US20180162922A1

公开(公告)日：2018-06-14

申请号：US15833778

申请日：2017-12-06

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： SEBASTIAN BUNK ,  DOMINIK MAURER ,  JENS FRITSCHE ,  CLAUDIA WAGNER ,  LEONIE ALTEN ,  FRANZISKA HOFFGAARD ,  MATHIAS FERBER

IPC: C07K14/725 ,  C12N5/0783 ,  A61K35/17

Abstract: The present invention relates to modified T cell receptor (TCR) α or β chains, or heterodimers comprising the same, wherein in the variable domain of said modified α or β chain, an amino acid at position 44 according to the IMGT numbering is substituted by another suitable amino acid in order to improve pairing of desired chains.

公开(公告)号：US20170312350A1

公开(公告)日：2017-11-02

申请号：US15461020

申请日：2017-03-16

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： DOMINIK MAURER ,  LEONIE ALTEN ,  SEBASTIAN BUNK

IPC: A61K39/00 ,  A61K45/06 ,  G01N33/574 ,  C07K14/725

CPC classification number: A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  C07K14/7051 ,  C07K14/70539 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/55 ,  C07K2319/60 ,  G01N33/574

Abstract: The present description relates to T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the present description relates to TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as IGF2BP3-001 have the amino acid sequence of KIQEILTQV (SEQ ID NO:1). The present description further relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180164315A1

公开(公告)日：2018-06-14

申请号：US15835095

申请日：2017-12-07

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： LEONIE ALTEN ,  SEBASTIAN BUNK ,  DOMINIK MAURER ,  Claudia WAGNER

IPC: G01N33/574 ,  C07K16/28 ,  G01N33/58 ,  A61K39/395 ,  A61K35/17

Abstract: The present invention relates to antigen recognizing constructs against a tumor associated antigen (TAA) derived from the target protein DDB1 and CUL4 associated factor 4-like 2 (DCAF4L2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the TAA of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.